KRRO
What one share of Korro Bio holds
Pharmaceutical Preparations
We are a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. We are generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient change to a single nucleoside (adenosine to an inosine edit).
Korro Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.20 |
|---|---|
| Profit | −$8.88 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$5.68 |
| Cash and investments | $9.38 |
| Book value | $7.02 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $0.00 | −$227.42 | $20.13 | −$230.36 | — | −$368.87 |
| 2023 | $0.00 | −$53.08 | $5.12 | −$49.12 | — | — |
| 2024 | $0.25 | −$9.37 | $2.01 | −$8.74 | — | $17.11 |
| 2025 | $0.68 | −$12.48 | $0.06 | −$8.42 | — | $5.46 |